Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00458887 · ClinicalTrials.gov registry record

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

A clinical trial of Unspecified Childhood Solid Tumor, Protocol Specific and Ototoxicity, sponsored by Children's Oncology Group.

Completed
Registry status
301
Enrollment target
20
Study locations

NCT00458887 is a study of Unspecified Childhood Solid Tumor, Protocol Specific and Ototoxicity that has completed, run by Children's Oncology Group. The registered enrollment target is 301 participants, below the 1,614-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00458887, a study of Unspecified Childhood Solid Tumor, Protocol Specific and Ototoxicity, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
301 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.

Interventions

  • PROCEDURE management of therapy complications

Study Locations (20)

Florida

  • Lee Cancer Care of Lee Memorial Health System - Fort Myers
  • Nemours Children's Clinic - Jacksonville
  • University of Miami Sylvester Comprehensive Cancer Center - Miami - Miami
  • Florida Hospital Cancer Institute at Florida Hospital Orlando - Orlando
  • Nemours Children's Clinic - Orlando - Orlando
  • Nemours Children's Clinic - Pensacola - Pensacola
  • All Children's Hospital - St. Petersburg
  • St. Joseph's Cancer Institute at St. Joseph's Hospital - Tampa

California

  • Childrens Hospital Los Angeles - Los Angeles
  • Southern California Permanente Medical Group - Los Angeles
  • Children's Hospital Central California - Madera
  • Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
  • Rady Children's Hospital - San Diego - San Diego
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Connecticut

  • Connecticut Children's Medical Center - Hartford
  • Yale Cancer Center - New Haven

Alabama

  • UAB Comprehensive Cancer Center - Birmingham

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Delaware

  • Alfred I. duPont Hospital for Children - Wilmington

Hawaii

  • Cancer Research Center of Hawaii - Honolulu

Trial Details

FieldValue
Enrollment Target 301 participants
Start Date 2007-05
Est. Completion 2017-02-28

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT00458887

The ClinicalTrials.gov registry entry for NCT00458887 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,614-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (81% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Unspecified Childhood Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which management of therapy complications is the first listed.

NCT00458887 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00458887 about?

NCT00458887 is a clinical study titled "Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin". RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.

What is the current status of trial NCT00458887?

This trial is currently completed. The enrollment target is 301 participants. The study started on 2007-05. Estimated completion is 2017-02-28.

What conditions does trial NCT00458887 study?

This clinical trial studies the following conditions: Unspecified Childhood Solid Tumor, Protocol Specific, Ototoxicity.

What interventions are being tested in trial NCT00458887?

The interventions under investigation include: management of therapy complications (PROCEDURE).

Who is sponsoring clinical trial NCT00458887?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00458887 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Unspecified Childhood Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.